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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYStatins improve recovery from traumatic brain injury and show promise in preventing Alzheimer disease. However, the mechanisms by
which statins may be therapeutic for neurological conditions are not fully understood. In this study, we present the initial evidence that
oral administration of simvastatin in mice enhances Wnt signaling in vivo. Concomitantly, simvastatin enhances neurogenesis in
cultured adult neural progenitor cells as well as in the dentate gyrus of adult mice. Finally, we find that statins enhance Wnt
signaling through regulation of isoprenoid synthesis and not through cholesterol. These findings provide direct evidence that Wnt
signaling is enhanced in vivo by simvastatin and that this elevation ofWnt signaling is required for the neurogenic effects of simvastatin.
Collectively, these data add to the growing body of evidence that statins may have therapeutic value for treating certain neurological
disorders.INTRODUCTION
A large body of evidence indicates that statins, a class of
drugs typically used to treat hyperlipidemia, are therapeu-
tically beneficial for neurological disorders. Statins have
been shown to improve outcome following traumatic brain
injury and stroke (Chen et al., 2003; Karki et al., 2009; Lu
et al., 2007; Mahmood et al., 2009; Wu et al., 2008). Simva-
statin rescues cerebrovascular and memory-related deficits
in mouse models of Alzheimer disease (AD) (Li et al.,
2006; Tong et al., 2009, 2012), and recent meta-analysis
of clinical studies concluded that statins provide a slight
benefit in the prevention of AD and all-type dementia
(Wong et al., 2013). While these effects have been attrib-
uted to reduction of inflammation, reduced oxidative
stress, upregulated PI3K/AKT signaling, and enhanced neu-
rogenesis, the mechanisms by which statins are beneficial
in neurological disorders are not fully understood.
Previously, we reported a chemical genetic screen that
revealed that several statins activate a b-catenin-responsive
luciferase reporter (BAR) in a cell-based assay (Biechele
et al., 2010). This result supports prior in vitro studies
that have shown that statins modulate Wnt/b-catenin
signaling (henceforth referred to as Wnt signaling) in
human neuronal cells (Salins et al., 2007), in rat mesangial
cells (Lin et al., 2008), and in mouse embryonic stem cells
(Qiao et al., 2011). Given that Wnt signaling is a key regu-
lator of adult hippocampal neurogenesis (Jang et al., 2013;SKuwabara et al., 2009; Lie et al., 2005; Luo et al., 2010; Mao
et al., 2009; Seib et al., 2013), we sought to determine
whether statin-mediated enhancement of the Wnt
pathway can occur in this region of the brain and to char-
acterize any downstream effects onneurogenesis.We chose
to focus on simvastatin (simva), as it is a lipophilic statin
capable of crossing the blood-brain barrier (Tamai and
Tsuji, 2000) and is commonly studied in neural contexts.
We find that simva enhances Wnt signaling in the adult
hippocampus and thatWnt signaling is required for statins
to enhance neuronal specification in differentiating adult
neural progenitor cells (aNPCs). Through examination of
various stage-specific markers in vivo, we determine that
simva treatment increases the number of newborn neurons
in the dentate gyrus (DG) by enhancing proliferation of
intermediate precursor cells (IPCs) in the subgranular
zone (SGZ). Finally, we determine that the effect of simva
on the Wnt pathway is independent of cholesterol and is
mediated by inhibition of isoprenoid biosynthesis.RESULTS
Simva Enhances Wnt Signaling In Vitro and In Vivo
We recently reported that lovastatin and fluvastatin
enhance Wnt signaling (Biechele et al., 2010). In the pre-
sent study, we extended our analysis to simva, a statin
of clinical relevance to neurological disease. To monitortem Cell Reports j Vol. 2 j 9–17 j January 14, 2014 j ª2014 The Authors 9
Figure 1. Simva Enhances Wnt Signaling
In Vitro and In Vivo
(A) Venus reporter expression in aNPCs
treated with various concentrations of
simva in combination with rcWNT3A
(20 ng/ml), counterstained with Hoechst
(scale bars, 100 mm).
(B) Quantification of Venus+ cells (n = 5
independent wells).
(C) Expression of Wnt target genes in aNPCs
treated with 5 mM simva or DMSO in com-
bination with rcWNT3A or CHAPS (n = 3
independent wells).
(D) b-gal staining of DG from BAT-GAL mice
treated with simva or DMSO, counterstained
with DAPI (left scale bars, 100 mm; right-
inset scale bars, 50 mm).
(E) Quantification of b-gal+ cell density (n =
7–8 mice per group).
(F) Real-time PCR analysis of Wnt target
genes in hippocampi of BAT-GAL mice (n = 3
mice per group).
Results are presented as mean ± SEM (B, C,
E, and F). Statistical analysis was performed
with the Student’s unpaired t test.
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driving expression of Venus fluorophore. Consistent with
prior studies (Wexler et al., 2009), we saw no reporter activ-
ity under basal culture conditions, and addition of simva
by itself did not induce reporter expression (not shown).
However, in combination with a low dose (20 ng/ml) of10 Stem Cell Reports j Vol. 2 j 9–17 j January 14, 2014 j ª2014 The Authorsrecombinant WNT3A ligand (rcWNT3A), simva promoted
a dose-dependent increase in the percentage of Venus+ cells
following 4 days of treatment (Figures 1A and 1B).
If, as suggested above, simva were able to synergize with
Wnt signaling, then onewould predict that such treatment
should increase the expression of endogenous Wnt target
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in combination with either rcWNT3A or vehicle control
(CHAPS), and used quantitative real-time PCR to monitor
the levels of two genes that are known to be directly regu-
lated by Wnt signaling in adult neural cells, Axin2 and
CyclinD1 (Mao et al., 2009). As expected, rcWNT3A pro-
moted increases in Axin2 and CyclinD1 expression
compared to CHAPS, while simva alone had negligible
effects. However, the expression of these genes was greatly
enhanced by the combination of simva and rcWNT3A,
similar to the synergy seen with the BAR reporter. We
observed a 7.7-fold increase inAxin2 and a 5.2-fold increase
in CyclinD1 expression (Figure 1C). Thus, both BAR
reporter and expression levels of b-catenin target genes
show that simva enhances Wnt signaling in cells where
the pathway is activated at a low level.
We then directly investigated whether dosing mice with
simva via oral gavage enhances Wnt signaling in the
brain. Based on our in vitro data, we focused on the DG
of the hippocampus, one of the germinal brain regions
where aNPCs reside and where WNT3A is secreted
throughout adulthood (Garbe and Ring, 2012; Lie et al.,
2005). We treated adult C57BL/6J mice harboring a
reporter transgene (BAT-GAL) that drives expression of
nuclear-targeted b-galactosidase (b-gal) in response to
Wnt signaling (Maretto et al., 2003), and which has
been used to measure Wnt signaling in the DG (Garbe
and Ring, 2012; Mazumdar et al., 2010). Based on
previous studies, we treated BAT-GAL mice with either
10 mg/kg simva or DMSO by oral gavage daily for
7 days (Chen et al., 2003; Karki et al., 2009). Mice were
sacrificed 4 hr after the final drug treatment. We observed
a 1.4-fold increase in the density of nuclei containing
b-gal in the DG of mice treated with simva (Figures 1D
and 1E), while the volume of the DG was unchanged
between treatment groups (not shown). To test whether
these results reflect changes in expression levels of Wnt
targets, we collected total RNA from the hippocampus
and performed real-time PCR analysis. We measured a
significant increase in the average expression of both
reporter gene LacZ and endogenous target gene Axin2 in
mice treated with simva compared with vehicle-treated
mice (Figure 1F). Together with the BAT-GAL immuno-
staining, these results demonstrate that systemic adminis-
tration of simva enhances Wnt signaling in the DG of
adult mice.
Simva Enhances Neuronal Specification via Wnt
Signaling
We then investigated the effect of simva on aNPCs during
differentiation. We induced differentiation in aNPCs as
described previously (Luo et al., 2010; Palmer et al.,
1999; Smrt et al., 2007), in the presence of drug treatmentStefor 4 days and stained for lineage-specific markers (Fig-
ure 2A). While simva slightly reduced the total number
of cells detected following differentiation (Figure 2B),
simva treatment lead to a 3.6-fold increase in the number
of TUJ1+ neurons and a significant decrease in the num-
ber of GFAP+ astroglial cells (Figures 2C and 2D). To
further assess the effect of simva on aNPC differentiation,
we measured expression of linage-specific genes using
real-time PCR. mRNA levels of the neuron-specific genes
Tuj1 and NeuroD1 were significantly increased following
differentiation in aNPCs treated with simva (Figure 2E).
Levels of the astroglial genes Gfap and Aqp4 were lower
in simva-treated aNPCs, but the difference was not statis-
tically significant (Figure 2F). These results, consistent
with previous reports of Wnt enhancement during
aNPC differentiation (Luo et al., 2010), indicate that
simva influences lineage specification in aNPCs toward
increased production of neurons and decreased produc-
tion of astroglia.
In order to test whether the effect of simva on aNPC dif-
ferentiation is due to enhanced Wnt signaling, we also
tested simva in combination with a Wnt pathway antago-
nist. For this, we employed the small molecule XAV939.
Importantly, XAV939 blocks simva-mediated enhance-
ment of Wnt signaling in aNPCs (Figure S1 available
online). We reasoned that if simva enhances neuronal
differentiation via enhanced Wnt signaling, then a combi-
nation of XAV939 and simva should not elicit this effect.
As expected, XAV939 treatment significantly decreased
the number of neurons formed following aNPC differenti-
ation. We found that in aNPCs treated concurrently with
XAV939 and simva, the percentage of TUJ1+ cells was
equivalent to DMSO-treated cells and significantly reduced
as compared to cells treated with simva alone (Figures 2A
and 2C). Additionally, levels of the neuronal genes Tuj1
and NeuroD1 were decreased with combined simva and
XAV939 treatment compared with DMSO (Figure 2D),
while levels of the astrocytic genes Gfap and Aqp4 where
not significantly changed (Figure 2E). These data demon-
strate that blocking Wnt signaling abolishes the ability of
simva to enhance neuronal differentiation and suggest
that this effect of simva is Wnt signaling-dependent.
Simva Enhances Adult Hippocampal Neurogenesis
Having observed that simva enhancesWnt signaling in the
DG of adult mice and increases neuronal specification in
cultured aNPCs, we next assessed the effects of the simva
treatment described above on in vivo hippocampal neuro-
genesis. To assess overall cell proliferation in the SGZ, we
first examined the DNA replication marker MCM2 (Fig-
ure 3A). Quantification of cell numbers using confocal z
stack images revealed that mice treated with simva
had 1.7-fold more MCM2+ cells per DG compared tom Cell Reports j Vol. 2 j 9–17 j January 14, 2014 j ª2014 The Authors 11
Figure 2. Simva Enhances Neuronal
Specification via Wnt Signaling
(A) Staining for astroglial marker GFAP and
neuronal marker TUJ1 in differentiated
aNPCs treated with DMSO, 5 mM simva,
2.5 mM XAV939, or a combination of simva
and XAV939, counterstained with Hoechst
(scale bars, 100 mm).
(B) Cell count for each condition following
differentiation.
(C) Quantification of TUJ1+ cells.
(D) Quantification of GFAP+ cells.
(E) Real-time PCR analysis of neuronal-
specific genes.
(F) Real-time PCR analysis of astroglial-
specific genes.
Results are presented as mean ± SEM,
n = 3 independent wells (B–F). Statistical
analysis as performed with the Student’s
unpaired t test. See also Figure S1.
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increase in DG cell proliferation affects the formation of
new neurons, we examined the immature neuron marker
DCX. We did not find a significant difference in the
number of DCX+ cells per DG for simva versus control
(not shown). However, when we injected mice with a
single dose of EdU (50 mg/kg) 24 hr prior to perfusion to
specifically label cells in S phase toward the end of treat-
ment, we saw that the number of DCX+/EdU+ cells per
DG was increased 1.4-fold with simva treatment (Figures12 Stem Cell Reports j Vol. 2 j 9–17 j January 14, 2014 j ª2014 The Authors3C and 3D). To test whether simva treatment affects cell
survival, we counted the apoptotic nuclei within the
same area of the DG. Cleaved caspase-3 (cCASP3) staining
revealed no significant difference in the number of
cCASP3+ cells per DG in simva-treated mice (Figure S2).
The increase in the number of proliferating cells within
the SGZ that we observed as a result of simva treatment
could be due to increased IPC proliferation or increased
production of IPCs from radial-glia like early precursors
(RGLs) (Bonaguidi et al., 2011). We looked to see what
Figure 3. Simva Enhances Adult Hippocampal Neurogenesis
(A) Staining for proliferation marker MCM2 in the DG of mice treated with simva or DMSO, counterstained with DAPI (scale bars, 50 mm).
(B) Quantification of MCM2 cell number.
(C) Costaining for immature neuron marker DCX in cells labeled with a single dose of EdU 24 hr prior to sacrifice. (Insets show colo-
calization, yellow arrows indicate DCX+/EdU+ cells; scale bars, 50 mm.)
(D) Quantification of DCX+/EdU+ cell number.
(E) Yellow arrow: activated early precursor cell (RGL), Nestin+/MCM2+ with radial morphology (scale bar, 25 mm).
(F) Yellow arrow: proliferating intermediate precursor cell (IPC), Nestin+/MCM2+ with horizontal morphology (scale bar, 25 mm).
(G) Quantification of activated RGL and proliferating IPC cell number.
Results are presented as mean ± SEM, n = 8 mice per group, statistical analysis performed with Student’s unpaired t test (B, D, and G).
(H–K) b-gal costaining with (H) mature neuron marker NEUN, (I) DCX, (J) astroglial and immature precursor marker GFAP, and (K) astrocyte
marker S100B. Scale bars, 50 mm.
Counterstaining with DAPI (A, C, E, F, and H–K). See also Figure S2.
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genitor marker Nestin alongside MCM2. Activated RGLs,
which asymmetrically divide to form new IPCs, were iden-
tified as Nestin+/MCM2+ with radial morphology (Fig-
ure 3E). Proliferating IPCs were identified as Nestin+/
MCM2+ cells with horizontal morphology (Figure 3F). We
observed a modest, but not statistically significant,
increase the number of activated RGLs per DG in simva-
treated mice. Meanwhile, the number of proliferating
IPCs per DG was increased 2-fold in simva-treated mice
(Figure 3G).
BAT-GAL staining revealed thatWnt signaling is active in
some, but not all, of the cells in the DG of both simva- and
control-treated mice (Figure 1D). To identify the cell types
that exhibit active Wnt signaling following simva treat-
ment, we costained tissue for b-gal and a panel of cell-
type-specific markers. We observed that a majority ofStenuclear b-gal expression occurred in cells labeled with the
mature neuron-specific protein NEUN in the granule cell
layer (GCL) (Figure 3H), with very little b-gal in immature
neurons (DCX+) (Figure 3I).We saw significant b-gal expres-
sion in GFAP+ cells in both the GCL and SGZ (Figure 3J).
WhileGFAP can label both astrocytes and immature precur-
sors, cells with nuclear b-gal expression were rarely labeled
with the astrocyte marker S100B (Figure 3K).
We found that simva increases overall cell proliferation
in the SGZ, leading to an increase in the number of newly
formed neurons. When we looked to delineate between
different progenitor pools, we found that IPC proliferation
was significantly increased. Additionally, we observedWnt
reporter expression in both GFAP+ and NEUN+ cells
following simva treatment. Taken together, these data sug-
gest that oral simva treatment enhances adult neurogenesis
in the mammalian hippocampus.m Cell Reports j Vol. 2 j 9–17 j January 14, 2014 j ª2014 The Authors 13
Figure 4. Simva Enhances Wnt Signaling via Depletion of Isoprenoids
(A) BAR luciferase assay in SH-SY5Y cells transfected with control (nontargeting) siRNA or one of three independent siRNAs targeting
HMGCR and treated with WNT3A CM or control CM.
(B) The sterol biosynthetic pathway is blocked by statins, leading to depletion of isoprenoids and cholesterol.
(C) BAR luciferase assay in SH-SY5Y cells treated with simva in combination with products of the sterol biosynthetic pathway: 10 mM GGPP
and 10 mM FPP, and 10 mM squalene.
Results are presented as mean ± SEM; n = 3 independent wells (A and C). Statistical analysis was performed with the Student’s unpaired
t test. See also Figures S3 and S4.
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of Isoprenoids
Finally, we investigated the mechanism by which simva
can enhance Wnt signaling. Statins antagonize HMG-
CoA-reductase (HMGCR), the rate-limiting enzyme in the
sterol biosynthetic pathway. This pathway is responsible
for de novo synthesis of cholesterol as well as isoprenoids
(Endo, 1992). To test whether inhibition of sterol biosyn-
thesis enhances Wnt signaling, we used small interfering
RNAs (siRNAs) to knock down HMGCR in human neuro-
blastoma (SH-SY5Y) cells harboring BAR driving luciferase.
Similar to our aNPC data, we found that simva enhances
Wnt signaling in these cells with a low dose of WNT3A
conditioned media (CM), but not with control CM (Fig-
ure S3). We tested three unique siRNAs to knock down
HMGCR (Figure S4) and a control nontargeting siRNA. Cells
transfected with HMGCR siRNAs and treated with WNT3A
CM showed significantly increased reporter induction
(Figure 4A).
DownstreamofHMGCR, sterol biosynthesis bifurcates to
produce either the cholesterol-precursor squalene or the
isoprenoids farnesyl pyrophosphate (FPP) and geranylger-
anyl pyrophosphate (GGPP) (Fears, 1981) (Figure 4B).
Statins, via inhibition of the sterol biosynthetic pathway,
deplete cellular pools of cholesterol, FPP, and GGPP
(Hughes, 1996). To test whether any of these products are
involved in simva enhancement of Wnt signaling, we
treated SH-SY5Y BAR cells with 5 mM simva, WNT3A CM,
and exogenous FPP, GGPP, or squalene. We reasoned that
if statin-mediated depletion of any of these metabolites14 Stem Cell Reports j Vol. 2 j 9–17 j January 14, 2014 j ª2014 The Authorscaused the enhancement of theWnt pathway, then adding
the responsible metabolite back to the cells would inhibit
the ability of simva to enhance BAR activity. Notably,
addition of 10 mMGGPP or 10 mMFPP to simva-treated cells
significantly reduced simva-mediated Wnt enhancement,
while 10 mM squalene did not have an effect (Figure 4C).
Since FPP is used to synthesize GGPP, the effect may be
due to depletion of GGPP alone or a combination of FPP
and GGPP depletion. Therefore, we conclude that simva
enhances Wnt signaling via depletion of isoprenoids and
not cholesterol.DISCUSSION
Simva is under investigation for its potential therapeutic
effects outside of hyperlipidemia treatment. While statins
have been reported to enhance Wnt signaling in vitro, it
was heretofore not known whether statins can enhance
this pathway in vivo and in the context of neurogenesis.
Here we provide evidence that oral simva treatment
enhances Wnt signaling in the mammalian adult hippo-
campus. This is significant in that aside from lithium, no
other clinically approved compound has been demon-
strated to enhanceWnt signaling in the brain (Zimmerman
et al., 2012).
The observations in this study are consistent with reports
of increased hippocampal neurogenesis due to both simva
treatment (Chen et al., 2003; Lu et al., 2007; Wu
et al., 2008) and increased Wnt signaling (as cited in
Stem Cell Reports
Simvastatin Promotes Neurogenesis by Enhancing Wntintroduction). Importantly, we demonstrate a link between
these phenomena by probingWnt’s role in simva enhance-
ment of neurogenesis in vitro, and subsequently investi-
gating the effect of enhanced Wnt signaling during
multiple stages of in vivo adult hippocampal neurogenesis.
While we showed a requirement for Wnt signaling in
increased neuronal differentiation among simva-treated
aNPCs, it remains possible that additional signaling path-
ways play a role in simva’s effect on overall neurogenesis.
Further, while others have demonstrated beneficial neuro-
logical effects of simva in disease models (as cited in intro-
duction), the present study was performed using healthy
animals and did notmonitor later stages of neuronal devel-
opment or behavioral outcomes.
To help map the biological connection between
enhanced Wnt signaling and enhanced neurogenesis, we
examined costaining of BAT-GAL with various cell-type-
specific markers following simva treatment. However, a
comparison showing differences in temporal expression
patterns between different in vivo Wnt reporters presents
a potential caveat to this approach (Garbe and Ring, 2012).
The mechanism underlying statin enhancement of Wnt
signaling had not been previously reported. Providing
initial insight, we show that HMGCR loss of function is suf-
ficient to enhance the Wnt pathway. Furthermore, we
demonstrate that simva acts onWnt signaling by depleting
isoprenoids, rather than through a cholesterol-dependent
mechanism. Prenylation guides membrane localization of
small GTPases such as RAS and RHO-associated kinases
and other signaling proteins (Zhang and Casey, 1996),
and serves as a regulatory mechanism for these enzymes
that can be targeted therapeutically (Gelb et al., 2006). To
this point, recent studies have measured an age-dependent
increase of isoprenoid levels in brains of mice (Hooff et al.,
2012) and have identified an overabundance of isopre-
noids in the brains of AD patients (Eckert et al., 2009).
The identity of the specific prenylated protein or proteins
responsible for the effect of simva on the Wnt pathway re-
mains elusive. However, there are a number of prenylated
proteins known to regulate Wnt signaling (e.g., RAC1
and RHOA) that may serve as candidates for future studies
(Schlessinger et al., 2009).EXPERIMENTAL PROCEDURES
BAR Venus Experiment with aNPCs
aNPCs were plated on polyornithine- (Sigma-Aldrich) and
laminin-coated (Life Technologies) optical imaging plates (Corn-
ing) in proliferation media containing FGF (Life Technologies)
and epidermal growth factor (EGF; PeproTech) (see Supplemental
Experimental Procedures). Drugs were added as indicated 24 hr
after plating. Following 4-day drug treatment, Hoechst 33342
dye (Sigma-Aldrich) was added at 1 mg/ml.SteMouse Experiments
Eight- to 10-week-old C57BL/6J WT and BAT-GAL mice were used
in this study. All animal-related procedures were approved by the
Institutional Animal Care and Use Committee of the University
of Washington and were conducted in accordance with the guide-
lines of theNational Institutes of Heath. For oral gavage, simvawas
dissolved in DMSO and diluted in 1% carboxymethylcellulose
(Sigma-Aldrich) in water. For EdU experiments, mice were injected
intraperitoneally with 50 mg/kg EdU dissolved in DMSO. For
details on tissue collection, see the Supplemental Experimental
Procedures.aNPC Differentiation
To induce differentiation, aNPCs were plated on polyornithine-
and laminin-coated optical imaging plates with differentiation
media containing 5 mM forskolin (Sigma-Aldrich) and 1 mM
retinoic acid (Sigma-Aldrich) and lacking EGF and fibroblast
growth factor (see Supplemental Experimental Procedures).Antibody Staining, Imaging, and Quantification
BAR Venus aNPCs were imaged with a fluorescence microscope
(Nikon), and antibody-stained aNPCs were imaged with a Nikon
A1 confocal microscope. TUJ1+ and GFAP+ aNPCs were manually
counted using ImageJ, and percentage was determined by dividing
by total number of nuclei. BAT-GAL+ cell density and DG volume
was determined using stereology software and semiautomated
counting with a fluorescence microscope. To quantify MCM2+,
DCX+, EdU+/DCX+, and Nestin+/MCM2+ cells we collected z
stacks and counted manually using ImageJ (see Supplemental
Experimental Procedures).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures and four figures and can be found with this article
online at http://dx.doi.org/10.1016/j.stemcr.2013.11.002.
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